Related Experiment Video

Updated: May 20, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Sex difference in the effect of obesity on prognosis for patients undergoing percutaneous coronary intervention

Zhi Jian Wang1, Ying Xin Zhao, Yu Yang Liu

  • 1Department of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, China.

Coronary Artery Disease
|July 26, 2012
PubMed

Insights

Obesity increases major adverse cardiovascular events (MACE) risk after percutaneous coronary intervention (PCI) in men, but this effect is less pronounced in women. Further research is needed to understand these sex-specific differences in cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Obesity Research
  • Interventional Cardiology

Background:

  • Obesity is a growing public health concern linked to cardiovascular disease.
  • Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.

Purpose of the Study:

  • To investigate the impact of obesity on long-term prognosis in men and women undergoing PCI.
  • To determine if sex influences the relationship between Body Mass Index (BMI) and adverse cardiovascular events post-PCI.

Main Methods:

  • A cohort study involving 3926 men and 2157 women undergoing PCI with drug-eluting stents.
  • Patients were categorized by BMI: normal (<25 kg/m²), overweight (25-29.9 kg/m²), and obese (≥30 kg/m²).
  • Primary endpoint was major adverse cardiovascular events (MACE), including cardiac death and nonfatal myocardial infarction, with a median follow-up of 26 months.

Main Results:

  • Obese men had a significantly higher MACE rate compared to normal-weight and overweight men (6.8% vs. 3.5% vs. 4.2%, P=0.001).
  • In women, no significant difference in MACE rates was observed across BMI categories (5.1% vs. 4.4% vs. 4.1%, P=0.684).
  • A graded increase in MACE risk with obesity severity was noted in men, while women with severe obesity (grade II/III) showed a significant increase in MACE risk.

Conclusions:

  • Body Mass Index (BMI) is associated with MACE risk in both men and women post-PCI.
  • The effect of BMI on MACE risk appears to be less pronounced in women compared to men.
  • These findings highlight potential sex-specific differences in cardiovascular risk associated with obesity following PCI.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...